The European Commission has approved a combination of Imfinzi (durvalumab) plus standard chemotherapy as a first-line treatment for people with extensive-stage small cell lung cancer (SCLC). Findings from the CASPIAN Phase 3 trial (NCT03043872) supported the decision. There, newly diagnosed patients with extensive-stage (widely spread) SCLC who received the combination lived significantly longer than those on chemo only. Response rates also were better with the Imfinzi combo. Imfinzi, marketed by AstraZeneca, is the first immunotherapy of…
You must be logged in to read/download the full post.
The post Imfinzi Approved in EU for Extensive-stage Small Cell Lung Cancer appeared first on BioNewsFeeds.